Verge Labs partnered with Tenacia Biotechnology under a CNS drug target identification agreement that uses foundation-model approaches and multimodal patient data. The data set cited in the report includes more than 12,000 brain transcriptomes across 6,500 patients with matched single-cell, proteomic, genomic, and clinical information. Verge said the collaboration is focused on prioritizing and characterizing new drug targets for selected central nervous system programs, with financial terms not disclosed. The deal is also described as the first collaboration for Verge since shifting away from developing its own therapeutics to supporting other companies’ drug-development efforts. For the discovery market, the transaction underscores how data-heavy computational platforms are being used to compress target validation timelines—especially in CNS, where biology is complex and patient heterogeneity is a key challenge.